Attachment # 7

Form Approved

OMB No. 0920-New

Expiration Date: XX/XX/XXXX

National Syringe Services Program Evaluation

**Survey Year 1**

Public reporting burden of this collection of information is estimated to average 35 minutes, including the time for reviewing instructions, administering/reading questions, and entering responses. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30333; Attn: OMB-PRA (0920-New)

**DAVE PURCHASE MEMORIAL SURVEY**

**QUESTIONNAIRE SECTIONS**

Contents

[Abbreviations 2](#_Toc63172711)

[Key Terms 2](#_Toc63172712)

[PRELIMINARY INFORMATION 3](#_Toc63172713)

[PROGRAM CHARACTERISTICS 5](#_Toc63172714)

[CLIENT CHARACTERISTICS 11](#_Toc63172715)

[COMMUNITY RELATIONS AND CHALLENGES 14](#_Toc63172716)

[SYRINGE COLLECTION, DISTRIBUTION, AND DISPOSAL 16](#_Toc63172717)

[PROVISION OF NALOXONE AND OTHER OVERDOSE REVERSAL MEDICATIONS 17](#_Toc63172718)

[PROVISION OF SERVICES 18](#_Toc63172719)

[2020 MODULE 25](#_Toc63172720)

[PROCESS EVALUATION 28](#_Toc63172721)

OVERVIEW

Abbreviations

|  |  |
| --- | --- |
| R | Respondent |
| DK | Don't know |
| REF | Refused to answer |
| NA | Not applicable (question asked of R but this is a codable response option) |
|  |  |
| EQ | Equal to |
| GT | Greater than |
| GE | Greater than or equal to |
| LE | Less than or equal to |
| LT | Less than |
| NE | Not equal to |

Key Terms

| **Term** | **Prefix / format** | **Definition** |
| --- | --- | --- |
| Calculated variable | CALC\_ | Item identifier (not prefix for variable name) for variables calculated by the CAPI program that appear in the CRQ. |
| Message | **INTERVIEWER**: | Message displayed to the interviewer that is not to be read to R. May be triggered by an edit check. Distinct from Interviewer Instruction. ‘FIELD NOTE’ indicates instructions that will be added as a field note rather than directly included in the question. |
| Filter question |  | A question that determines whether the respondent should receive subsequent question or set of questions, typically on a related topic. |
| Logic Check | Check\_ | Logic that must be checked (by the CAPI program) in order to determine proper routing to the next item in the CAPI programmed questionnaire. |
| Interviewer instruction |  | Instruction to interviewer regarding survey administration. Standard instructions are ‘Give Respondent Flashcard {letter}', ‘READ choices', ‘DO NOT READ choices', & ‘CHECK ALL that apply'. |
| Introductory statement | INTRO\_ | Transitional statement read to R at the beginning of a new topic (e.g., Section, set of questions, etc.). Prefix is followed by section abbreviation, series, or first item in set to which it applies. |
| Range |  | Range of valid response values for items collecting or computing numeric data. E.g., the valid range of responses to number of sex partners in past 12 months is 0 to 7000. |
| Section |  | Section of the Questionnaire. Each section has a unique two letter abbreviation. |
| Soft Edit Check | SoftEdit\_ | A check to determine whether the response entered is implausible. If yes, CAPI program displays message to interviewer; program may advance after closing the error message dialog box. |

**DAVE PURCHASE MEMORIAL SURVEY**

PRELIMINARY INFORMATION

|  |  |
| --- | --- |
| **INTRO\_OMB.** | Public reporting burden of this collection of information is estimated to average 35 minutes per survey, including the time for reviewing instructions, administering questions and entering responses. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, US8-4, Atlanta, Georgia 30333; Attn: OMB-PRA (0920-New). |

|  |  |  |  |
| --- | --- | --- | --- |
| **CALC\_YR** | **Hidden variable: Year of recall period. This is the period that the participant will be asked to recall throughout the survey. This needs to be updated manually by survey staff each time the survey is administered.**  *Field note: Must be 4 digits.* | | |
| YEAR | Recall year | |  |
|  | **\_ \_ \_ \_** |  |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **PI1.** | **Are you completing this survey by yourself or by speaking with an interviewer?** | | |
| ADMIN | Mode of administration | |  |
|  | Completing survey myself | 0 |  |
|  | Completing survey with interviewer | 1 |  |

|  |  |
| --- | --- |
| **Check\_INTRO.** | If R self-administering survey (PI1 [ADMIN] EQ 0), go to INTRO\_SA.  Else, go to INTRO\_IA. |

|  |  |
| --- | --- |
| **INTRO\_SA.** | Thank you for taking the time to complete this program survey.  When answering questions, please refer to the period from January 1, [YEAR], to December 31, [YEAR] unless otherwise stated. If program data are not available, please use your best estimate to complete the questions below. If your program only operated during some of the specified time period, please provide information reflective of the time period(s) during which your program did operate.  If you need any clarifications about any of the questions in this survey or how this information will be used, please contact [project coordinator name, phone, email].  If you need to step away, **PLEASE REMEMBER TO SAVE YOUR SURVEY,** as not saving it will result in losing your responses. To save, first click on the save button at the bottom of the screen. You will then be prompted to enter an email address and a link will be sent to you to continue the survey later. |

|  |  |
| --- | --- |
| **INTRO\_IA.** | Thank you for taking the time to complete this program survey.  When answering questions, please refer to the period from January 1, [YEAR], to December 31, [YEAR] unless otherwise stated. If program data are not available, please use your best estimate to complete the questions below. If your program only operated during some of the specified time period, please provide information reflective of the time period(s) during which your program did operate.  If you need any clarifications about any of the questions in this survey or how this information will be used, please let me know.  During the survey, you may need to refer to your records to answer some questions. If you are unable to answer a question today, but later find the answer in your records, you can reach us later to provide this additional information by contacting [project coordinator name, phone, email]. |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **CALC\_SDATE** | | **Automatic, hidden variable: Survey date (today)** | |  | |
|  | | Automatic start date | |  | |
|  | **\_ \_ / \_ \_ / \_ \_ \_ \_** | |  | |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **CALC\_START** | **Automatic, hidden variable: Start time of survey** | |  |
|  | Preliminary information: Start time | |  |
|  | **\_\_ : \_\_** |  |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **PI2.** | **What is the name of your program?**  *[FIELD NOTE: IF REFUSED, LEAVE BLANK]* |  | |
| PROGNAM | Name of program |  | |
|  | \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ | |
|  | {text response; max characters = 100} | | |

|  |  |  |  |
| --- | --- | --- | --- |
| **PI3a.** | **What month and year did the program start? Start by selecting the month. If you do not remember the exact month, please provide your best estimate.** | | |
| SDATE\_M | SDATE month | |  |
|  | January | 1 |  |
|  | February | 2 |  |
|  | March | 3 |  |
|  | April | 4 |  |
|  | May | 5 |  |
|  | June | 6 |  |
|  | July | 7 |  |
|  | August | 8 |  |
|  | September | 9 |  |
|  | October | 10 |  |
|  | November | 11 |  |
|  | December | 12 |  |
|  | Don't Know | 99 |  |
|  | Refuse to Answer | 77 |  |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **PI3b.** | | **Enter the year. If you do not remember the exact year, please provide your best estimate.**  **Please enter four digits.**  *[FIELD NOTE: IF REFUSED OR DON’T KNOW, LEAVE BLANK]* | | |  |
| SDATE\_Y | | SDATE year | | |  |
|  | **---- ---- ---- -----** |  | |  |
|  | Range | | 1950-[YEAR] |  |

|  |  |
| --- | --- |
| **SoftEdit\_SDATE\_Y** | If [SDATE\_Y] > [YEAR], then display error message: “The year the SSP started is later than [YEAR]. Please confirm that this year is accurate.” |

|  |  |
| --- | --- |
| **INTRO\_PI.** | First, we would like to ask a series of questions about your program and the services your program provided between January 1, [YEAR], and December 31, [YEAR]. Following these questions, we will then ask a few of the same questions about 2020. The COVID-19 pandemic likely impacted program operations and services provided by programs nationwide during 2020, so this information will be extremely important to help understand these impacts and the continuing challenges to programs moving forward. |

|  |  |  |  |
| --- | --- | --- | --- |
| **PI4.** | **Did your program provide any services at any time between January 1, [YEAR], and December 31, [YEAR]?** | | |
| OPRCL | Operated during recall period | |  |
|  | No | 0 |  |
|  | Yes | 1 |  |

|  |  |
| --- | --- |
| **Check\_PI4.** | If R did not operate at any time during the recall period (PI4 [OPRCL] EQ 0), go to INTRO\_MD1.  Else, go to INTRO\_PC. |

PROGRAM CHARACTERISTICS

|  |  |
| --- | --- |
| **INTRO\_PC.** | The next set of questions is about your program background and overall set-up. All information is important, and we appreciate your time and effort in completing this survey. However, we understand if you cannot answer some of these questions; in these situations, you have an option to select “don’t know” or “refuse to answer” responses, whichever best applies. |

|  |  |  |  |
| --- | --- | --- | --- |
| **S\_TIME1** | **Automatic hidden variable: Respondent start time** | |  |
|  | Respondent start time | |  |
|  | **\_\_ : \_\_** |  |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **PC1.** | **Was your program operated by a…**  **Select all that apply.** | | |
| OPBY | Program operator | |  |
|  | Community-based organization |  |  |
|  | City health department |  |  |
|  | County health department |  |  |
|  | State health department |  |  |
|  | Health care organization |  |  |
|  | Academic institution or hospital |  |  |
|  | Volunteers only |  |  |
|  | Other (please specify) |  |  |
|  | Refuse to Answer | 7 |  |

|  |  |
| --- | --- |
| **Check\_PC1spec.** | If R selected ‘Other (please specify)’ (PC1(7) [OPBY(7)] EQ 1), go to PC1spec [OPBY\_S].  Else, go to PC2 [SFUND]. |

|  |  |  |  |
| --- | --- | --- | --- |
| **PC1spec.** | **Specify other program operator.** |  | |
| OPBY\_S | Specify other program operator |  | |
|  | \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ | |
|  | {text response; max characters = 100} | | |

|  |  |  |  |
| --- | --- | --- | --- |
| **PC2.** | **What were your program’s sources of funding?**  **Select all that apply.** | | |
| SFUND | Sources of funding | |  |
|  | City government |  |  |
|  | County government |  |  |
|  | State government |  |  |
|  | Federal government |  |  |
|  | Non-profit foundation/organization |  |  |
|  | Individual donations |  |  |
|  | Personal funds from program managers or staff |  |  |
|  | Corporate donation |  |  |
|  | Other (please specify) |  |  |
|  | Don’t Know | 99 |  |
|  | Refuse to Answer | 77 |  |

|  |  |
| --- | --- |
| **Check\_PC2spec.** | If R selected ‘Other (please specify)’ (PC2(9) [SFUND(9)] EQ 1), go to PC2spec [SFUND\_S].  Else, go to PC3 [BUDGET]. |

|  |  |  |  |
| --- | --- | --- | --- |
| **PC2spec.** | **Specify other source of funding.** |  | |
| SFUND\_S | Specify other funding source |  | |
|  | \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ | |
|  | {text response; max characters = 100} | | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **PC3.** | | **What was your total program budget? If your program is part of a larger, multi-service organization, please only provide the budget for your part of the program. Please provide the best estimate to your knowledge.** | | |
| BUDGET | | Total program budget | |  |
|  | Less than $25,000 | 1 |  |
|  | $25,000–$100,000 | 2 |  |
|  | $100,001–$250,000 | 3 |  |
|  | $250,001–$500,000 | 4 |  |
|  | $500,001–$1 million | 5 |  |
|  | Between $1 million and $2 million | 6 |  |
|  | $2 million or more | 7 |  |
|  | Don’t Know | 99 |  |
|  | Refuse to Answer | 77 |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **PC4.** | **Did your program employ any full-time paid staff (that is, those working 30 hours per week or more)?** | | |
| FTSTAF | Full-time paid staff | |  |
|  | No | 0 |  |
|  | Yes | 1 |  |
|  | Refuse to Answer | 7 |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **PC5.** | **Did your program have any paid employees who formerly or currently injected drugs? Include paid outreach workers and those paid with stipends or salaries.** | | |
| PWIDST | Current or former PWID staff | |  |
|  | No | 0 |  |
|  | Yes | 1 |  |
|  | Don’t Know………………………………………………………………………………. | 9 |  |
|  | Refuse to Answer | 7 |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **PC6.** | **Did your program have any volunteers who formerly or currently injected drugs? Include outreach volunteers.** | | |
| PWIDVL | Current or former PWID volunteers | |  |
|  | No | 0 |  |
|  | Yes | 1 |  |
|  | Don’t Know………………………………………………………………………………. | 9 |  |
|  | Refuse to Answer | 7 |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **PC7.** | | **What were your program’s total hours of operation in a typical week? If your program had more than one location (including mobile locations), consider the hours of operation for the overall program. For example, if your program had 3 locations, and each was open from 1-5pm for 5 days per week, that would be 20 hours, not 60 hours, of overall coverage for that week. If you do not know or prefer not to answer, you may leave the response blank.** | | |
| NUMHRS | | Number of hours per week | |  |
|  | \_\_ \_\_ \_\_ |  |  |
|  | Range | 0-168 |  |

|  |  |
| --- | --- |
| **INTRO\_GEO.** | To help us understand geographic coverage of syringe services programs, please enter the state and county(ies) where your program operates. If your program has multiple locations, please list counties for all locations. Please also consider mobile units in your responses. |

|  |  |  |  |
| --- | --- | --- | --- |
| **PC8a.** | **Please specify the state(s) or territory(ies) where your program is located: Select all that apply.** | |  |
| SSPSTAT | State(s) or territory(ies) | |  |
|  | Alabama | 01 |  |
|  | Alaska | 02 |  |
|  | Arizona | 04 |  |
|  | Arkansas | 05 |  |
|  | California | 06 |  |
|  | Colorado | 08 |  |
|  | Connecticut | 09 |  |
|  | Delaware | 10 |  |
|  | District of Columbia | 11 |  |
|  | Florida | 12 |  |
|  | Georgia | 13 |  |
|  | Hawaii | 15 |  |
|  | Idaho | 16 |  |
|  | Illinois | 17 |  |
|  | Indiana | 18 |  |
|  | Iowa | 19 |  |
|  | Kansas | 20 |  |
|  | Kentucky | 21 |  |
|  | Louisiana | 22 |  |
|  | Maine | 23 |  |
|  | Maryland | 24 |  |
|  | Massachusetts | 25 |  |
|  | Michigan | 26 |  |
|  | Minnesota | 27 |  |
|  | Mississippi | 28 |  |
|  | Missouri | 29 |  |
|  | Montana | 30 |  |
|  | Nebraska | 31 |  |
|  | Nevada | 32 |  |
|  | New Hampshire | 33 |  |
|  | New Jersey | 34 |  |
|  | New Mexico | 35 |  |
|  | New York | 36 |  |
|  | North Carolina | 37 |  |
|  | North Dakota | 38 |  |
|  | Ohio | 39 |  |
|  | Oklahoma | 40 |  |
|  | Oregon | 41 |  |
|  | Pennsylvania | 42 |  |
|  | Puerto Rico | 72 |  |
|  | Rhode Island | 44 |  |
|  | South Carolina | 45 |  |
|  | South Dakota | 46 |  |
|  | Tennessee | 47 |  |
|  | Texas | 48 |  |
|  | US Virgin Islands | 78 |  |
|  | Utah | 49 |  |
|  | Vermont | 50 |  |
|  | Virginia | 51 |  |
|  | Washington | 53 |  |
|  | West Virginia | 54 |  |
|  | Wisconsin | 55 |  |
|  | Wyoming | 56 |  |
|  | Refuse to Answer | 77 |  |

|  |  |  |
| --- | --- | --- |
| **PC8b.** | **In which counties does your program provide services? Please include brick and mortar locations, mobile services, deliveries, and other ways you provide services. If you do not know or prefer not to answer, you may leave the response blank.** | |
| SSPCNTY | County(ies) |  |
|  | \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ | |
|  | {text response; max characters = 255} | |

|  |  |  |  |
| --- | --- | --- | --- |
| **PC9.** | **Did your program serve communities that you would consider urban, suburban, or rural? Please consider all the locations in which your program operates and select all that apply.** | | |
| SRVAREA | Service area type | |  |
|  | Urban |  |  |
|  | Suburban |  |  |
|  | Rural |  |  |
|  | Refuse to Answer | 7 |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **PC10.** | **How did your program deliver services? If your program had more than one location or service delivery type, select all that apply.** | | |
| SDELIV | Service delivery type | |  |
|  | Brick and mortar building/storefront |  |  |
|  | Mobile unit, such as an RV, van, or car |  |  |
|  | Tent or outdoor area |  |  |
|  | Home delivery |  |  |
|  | “Backpack” delivery |  |  |
|  | Mail order |  |  |
|  | Syringe vending machine |  |  |
|  | Other (please describe) |  |  |
|  | Don’t Know | 99 |  |
|  | Refuse to Answer | 77 |  |

|  |  |
| --- | --- |
| **Check\_PC10spec.** | If R selected ‘Other (please describe)’ (PC10(8) [SDELIV(8)] EQ 1), go to PC10spec [SDELIV\_S].  Else, go to PC11 [DSRPT]. |

|  |  |  |  |
| --- | --- | --- | --- |
| **PC10spec.** | **Specify other service delivery type.** |  | |
| SDELIV\_S | Specify other service delivery type |  | |
|  | \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ | |
|  | {text response; max characters = 100} | | |

|  |  |  |  |
| --- | --- | --- | --- |
| **PC11.** | **Did your program have to stop providing services for any period of time between January 1, [YEAR], and December 31, [YEAR] (that is, you did not provide services for at least one day or more when you had expected to be open)?** | | |
| DSRPT | Stop providing services | |  |
|  | No | 0 |  |
|  | Yes | 1 |  |
|  | Don’t Know | 9 |  |
|  | Refuse to Answer | 7 |  |

|  |  |
| --- | --- |
| **Check\_PC12.** | If R had to stop providing services (PC11 [DSRPT] EQ 1), go to PC12 [WHYDSRP]. Else, go to PC13 [INEVAL]. |

|  |  |  |  |
| --- | --- | --- | --- |
| **PC12.** | **Please choose the reason(s) for the disruption.**  **Select all that apply.** | | |
| WHYDSRP | Why services disrupted | |  |
|  | Inadequate funding for materials or supplies |  |  |
|  | Inadequate funding for operations |  |  |
|  | Lack of personnel to staff the program |  |  |
|  | Legal or political intervention |  |  |
|  | COVID-19 pandemic |  |  |
|  | Other (please describe) |  |  |
|  | Don’t Know | 9 |  |
|  | Refuse to Answer | 7 |  |

|  |  |
| --- | --- |
| **Check\_PC12spec.** | If R selected ‘Other (please describe)’ (PC12(6) [WHYDSRP(6)] EQ 1), go to PC12spec [WHYDSRP\_S].  Else, go to PC13 [INEVAL]. |

|  |  |  |  |
| --- | --- | --- | --- |
| **PC12spec.** | **Specify other reason for disruption(s) to services.** |  | |
| WHYDSRP\_S | Specify other disruption |  | |
|  | \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ | |
|  | {text response; max characters = 100} | | |

|  |  |  |  |
| --- | --- | --- | --- |
| **PC13.** | **Did your program review your program’s data for monitoring or evaluation purposes between January 1, [YEAR], and December 31, [YEAR]?** | | |
| INEVAL | Did program review internal data | |  |
|  | No | 0 |  |
|  | Yes | 1 |  |
|  | Refuse to Answer | 7 |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **PC14.** | **What computer software program did you use to manage your program’s data? Select all that apply.** | | |
| SFTWR | Software to manage client data | |  |
|  | None |  |  |
|  | Excel |  |  |
|  | Access |  |  |
|  | Neo360 |  |  |
|  | REDCap |  |  |
|  | Qualtrics |  |  |
|  | SurveyMonkey |  |  |
|  | Other (please describe) |  |  |
|  | Refuse to Answer | 77 |  |

|  |  |
| --- | --- |
| **Check\_PC14spec.** | If R selected ‘Other (please describe)’ (PC14 [SFTWR] EQ 8), go to PC14spec [SFTWR\_S].  Else, go to PC15 [UNIQID]. |

|  |  |  |  |
| --- | --- | --- | --- |
| **PC14spec.** | **Specify other software used to manage client data.** |  | |
| SFTWR\_S | Specify other software |  | |
|  | \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ | |
|  | {text response; max characters = 100} | | |

|  |  |  |  |
| --- | --- | --- | --- |
| **PC15.** | **Did your program assign each client a unique ID?** | | |
| UNIQID | Did program assign unique ID | |  |
|  | No | 0 |  |
|  | Yes | 1 |  |
|  | Refuse to Answer | 7 |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **PC16.** | | **How many unique clients did your program serve? Please provide the best estimate to your knowledge. If you do not know or prefer not to answer, you may leave the response blank.** | | |
| NUMCLI | | Number of unique clients | |  |
|  | \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ |  |  |
|  | Range | 0-99999999 |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **PC17.** | **Did your program have residency restrictions on who could access services, that is, only people from certain geographic locations could receive services from your program?** | | |
| RESRSTR | Residency restrictions | |  |
|  | No | 0 |  |
|  | Yes | 1 |  |
|  | Don’t Know | 9 |  |
|  | Refuse to Answer | 7 |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **PC18.** | **Did your program require clients to provide identifying documents (for example, a driver’s license) to enroll or receive services?** | | |
| IDDOC | Require identifying documents | |  |
|  | No | 0 |  |
|  | Yes | 1 |  |
|  | Don’t Know | 9 |  |
|  | Refuse to Answer | 7 |  |



CLIENT CHARACTERISTICS

|  |  |
| --- | --- |
| **INTRO\_CC.** | The next questions are about the characteristics of the clients served by your program. As a reminder, as you answer these questions, please think about your program’s operations between January 1, [YEAR], and December 31, [YEAR]. |

|  |  |  |  |
| --- | --- | --- | --- |
| **CC1.** | **Which demographic groups did your program reach in [YEAR]? Select all that apply.** | | |
| DEMSRV | Demographic groups served | |  |
|  | Cisgender women |  |  |
|  | Cisgender men |  |  |
|  | Transgender women |  |  |
|  | Transgender men |  |  |
|  | Genderqueer/non-binary persons |  |  |
|  | American Indian or Alaska Native persons |  |  |
|  | Asian persons |  |  |
|  | Black or African American persons |  |  |
|  | Hispanic or Latinx persons |  |  |
|  | Native Hawaiian or Other Pacific Islander persons |  |  |
|  | White persons |  |  |
|  | Persons aged <18 years |  |  |
|  | Persons aged 18 to 29 years |  |  |
|  | Persons aged 30 to 39 years |  |  |
|  | Persons aged ≥40 years |  |  |
|  | Lesbian, gay, bisexual, or queer persons |  |  |
|  | Other (please describe) |  |  |
|  | Refuse to Answer | 77 |  |

|  |  |
| --- | --- |
| **Check\_CC1spec.** | If R selected ‘Other (please describe)’ (CC1 [DEMSRV] EQ 16), go to CC1spec [DEMSRV\_S].  Else, go to CC2 [DEMRCH]. |

|  |  |  |  |
| --- | --- | --- | --- |
| **CC1spec.** | **Specify other demographic group reached.** |  | |
| DEMSRV\_S | Specify other group |  | |
|  | \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ | |
|  | {text response; max characters = 100} | | |

|  |  |  |  |
| --- | --- | --- | --- |
| **CC2.** | **Which demographic groups in your community did your program have difficulty reaching in [YEAR]? Select all that apply.** | | |
| DEMRCH | Difficulty reaching demographic groups | |  |
|  | Cisgender men |  |  |
|  | Cisgender women |  |  |
|  | Transgender men |  |  |
|  | Transgender women |  |  |
|  | Genderqueer/non-binary persons |  |  |
|  | American Indian or Alaska Native persons |  |  |
|  | Asian persons |  |  |
|  | Black or African American persons |  |  |
|  | Hispanic or Latinx persons |  |  |
|  | Native Hawaiian or Other Pacific Islander persons |  |  |
|  | White persons |  |  |
|  | Persons aged <18 years |  |  |
|  | Persons aged 18 to 29 years |  |  |
|  | Persons aged 30 to 39 years |  |  |
|  | Persons aged ≥40 years |  |  |
|  | Lesbian, gay, bisexual, or queer persons |  |  |
|  | Other (please describe) |  |  |
|  | Refuse to Answer | 77 |  |

|  |  |
| --- | --- |
| **Check\_CC2spec.** | If R selected ‘Other (please describe)’ (CC2 [DEMRCH] EQ 16), go to CC2spec [DEMRCH\_S].  Else, go to CC3 [DEMRCH]. |

|  |  |  |  |
| --- | --- | --- | --- |
| **CC2spec.** | **Specify other demographic group your program had difficulty reaching.** |  | |
| DEMRCH\_S | Specify other group |  | |
|  | \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ | |
|  | {text response; max characters = 100} | | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **CC3.** | | **Approximately what percentage of your clients did not have health insurance? Please use your records if available but provide your best estimate if no records are kept or are not readily available.** | | |
| INSUR | | Client insurance | |  |
|  | Less than 25% | 1 |  |
|  | 25-50% | 2 |  |
|  | 51-75% | 3 |  |
|  | More than 75% | 4 |  |
|  | Don’t Know | 9 |  |
|  | Refuse to Answer | 7 |  |

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **CC4.** | | **For each of the following substances, please indicate the approximate percentage of your clients who were injecting each substance on a weekly or more frequent basis. Please use your records if available but provide your best estimate if no records are kept or are not readily available.** | | | | | | | | |
| INJDRUG | | Substances injected by clients | | | | |  | | | |
|  | |  | None | Less than 25% | 25-50% | 51-75% | | More than 75% | Don’t Know | Refuse to Answer |
| INJDRUGA | Heroin, by itself |  |  |  |  | |  |  |  |
| INJDRUGB | Speedball, which is heroin and cocaine together |  |  |  |  | |  |  |  |
| INJDRUGC | Goofball, which is heroin and methamphetamine together |  |  |  |  | |  |  |  |
| INJDRUGD | Methamphetamine, by itself, also known as meth or speed |  |  |  |  | |  |  |  |
| INJDRUGE | Fentanyl, by itself or in combination with other drugs |  |  |  |  | |  |  |  |
| INJDRUGF | Powder cocaine, by itself |  |  |  |  | |  |  |  |
| INJDRUGG | Crack cocaine, by itself |  |  |  |  | |  |  |  |
| INJDRUGH | Painkillers, such as Oxycontin, Dilaudid, or Percocet |  |  |  |  | |  |  |  |
| INJDRUGI | Benzodiazepines or other downers, such as Valium, Xanax, or Klonopin |  |  |  |  | |  |  |  |
| INJDRUGJ | Other 1 (please describe) |  |  |  |  | |  |  |  |
| INJDRUGK | Other 2 (please describe) |  |  |  |  | |  |  |  |
| INJDRUGL | Other 3 (please describe) |  |  |  |  | |  |  |  |

|  |  |
| --- | --- |
| **Check\_CC4specA.** | If R selected ‘Other 1 (please describe)’ (CC4 [INJDRUGJ]), go to CC4specA [INJDRUGJ\_S].  Else, go to Check\_CC4specB. |

|  |  |  |  |
| --- | --- | --- | --- |
| **CC4specA.** | **From the previous question, specify ‘Other 1’ substance injected by clients.** |  | |
| INJDRUGJ\_S | Specify other substance injected |  | |
|  | \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ | |
|  | {text response; max characters = 100} | | |

|  |  |
| --- | --- |
| **Check\_CC4specB.** | If R selected ‘Other 2 (please describe)’ (CC4 [INJDRUGK]), go to CC4specB [INJDRUGK\_S].  Else, go to Check\_CC4specC. |

|  |  |  |  |
| --- | --- | --- | --- |
| **CC4specB.** | **From the previous question, specify ‘Other 2’ substance injected by clients.** |  | |
| INJDRUGK\_S | Specify other substance injected |  | |
|  | \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ | |
|  | {text response; max characters = 100} | | |

|  |  |
| --- | --- |
| **Check\_CC4specC.** | If R selected ‘Other 3 (please describe)’ (CC4 [INJDRUGL]), go to CC4specC [INJDRUGL\_S].  Else, go to INTRO\_CR. |

|  |  |  |  |
| --- | --- | --- | --- |
| **CC4specC.** | **From the previous question, specify ‘Other 3’ substance injected by clients.** |  | |
| INJDRUGL\_S | Specify other substance injected |  | |
|  | \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ | |
|  | {text response; max characters = 100} | | |

COMMUNITY RELATIONS AND CHALLENGES

|  |  |
| --- | --- |
| **INTRO\_CR.** | The next questions are about your program’s relationships with members of the community and any related challenges. As a reminder, as you answer these questions, please think about your program’s operations between January 1, [YEAR], and December 31, [YEAR]. |

|  |  |  |  |
| --- | --- | --- | --- |
| **CR1.** | **Which individuals or types of organizations advocated for your program or provided any type of support? Select all that apply.** | | |
| SUPADV | Sources of support or advocacy | |  |
|  | Local health officials |  |  |
|  | Law enforcement |  |  |
|  | HIV or other medical providers |  |  |
|  | Religious organizations |  |  |
|  | Local politicians |  |  |
|  | Local residents |  |  |
|  | Drug user unions |  |  |
|  | Other community-based organizations |  |  |
|  | Other (please describe) |  |  |
|  | No advocate support |  |  |
|  | Refuse to Answer | 77 |  |

|  |  |
| --- | --- |
| **Check\_CR1spec.** | If R selected ‘Other (please describe)’ (CR1(8) [SUPADV(8)] EQ 1), go to CR1spec [SUPADV\_S].  Else, go to CR2 [CHLNG]. |

|  |  |  |  |
| --- | --- | --- | --- |
| **CR1spec.** | **Specify other source of support** |  | |
| SUPADV\_S | Specify other source of support |  | |
|  | \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ | |
|  | {text response; max characters = 100} | | |

|  |  |  |  |
| --- | --- | --- | --- |
| **CR2.** | **What types of external challenges did your program face, not including challenges related to funding? Select all that apply.** | | |
| ECHLNG | Types of external challenges | |  |
|  | Limited/no law enforcement support |  |  |
|  | Active police harassment/arrest of program clients |  |  |
|  | Program operations disrupted by government or law enforcement |  |  |
|  | Local policy/law that restricts program services |  |  |
|  | Lack of support from local health officials |  |  |
|  | Lack of community support |  |  |
|  | Active community harassment |  |  |
|  | COVID-19 pandemic |  |  |
|  | Other (please describe) |  |  |
|  | Did not face external challenges |  |  |
|  | Refuse to Answer | 77 |  |

|  |  |
| --- | --- |
| **Check\_CR2spec.** | If R selected ‘Other (please describe)’ (CR2(9) [ECHLNG(9)] EQ 1), go to CR2spec [ECHLNG\_S].  Else, go to CR3 [ICHLNG]. |

|  |  |  |  |
| --- | --- | --- | --- |
| **CR2spec.** | **Specify other external challenges** |  | |
| ECHLNG\_S | Specify other external challenges |  | |
|  | \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ | |
|  | {text response; max characters = 255} | | |

|  |  |  |  |
| --- | --- | --- | --- |
| **CR3.** | **What types of internal challenges did your program face? Select all that apply.** | | |
| ICHLNG | Types of internal challenges | |  |
|  | Staff burnout |  |  |
|  | Staff shortage |  |  |
|  | Limited/no funding |  |  |
|  | Limited/no resources or supplies (other than funding) |  |  |
|  | Other (please describe) |  |  |
|  | Did not face internal challenges |  |  |
|  | Refuse to Answer | 77 |  |

|  |  |
| --- | --- |
| **Check\_CR3spec.** | If R selected ‘Other (please describe)’ (CR3(5) [ICHLNG(5)] EQ 1), go to CR3spec [ICHLNG\_S].  Else, go to CR4 [RLHO]. |

|  |  |  |  |
| --- | --- | --- | --- |
| **CR3spec.** | **Specify other internal challenges** |  | |
| ICHLNG\_S | Specify other internal challenges |  | |
|  | \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ | |
|  | {text response; max characters = 255} | | |

|  |  |  |  |
| --- | --- | --- | --- |
| **CR4.** | **How would you describe your program’s relationship with your local health department(s)?** | | |
| RLHO | Relationship with local health officials | |  |
|  | Very good | 1 |  |
|  | Somewhat good | 2 |  |
|  | Neither good nor poor | 3 |  |
|  | Somewhat poor | 4 |  |
|  | Very poor | 5 |  |
|  | Nonexistent | 6 |  |
|  | Refuse to Answer | 7 |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **CR5.** | **How would you describe your program’s relationship with law enforcement?** | | |
| RLAW | Relationship with law enforcement | |  |
|  | Very good | 1 |  |
|  | Somewhat good | 2 |  |
|  | Neither good nor poor | 3 |  |
|  | Somewhat poor | 4 |  |
|  | Very poor | 5 |  |
|  | Nonexistent | 6 |  |
|  | Refuse to Answer | 7 |  |

SYRINGE COLLECTION, DISTRIBUTION, AND DISPOSAL

|  |  |
| --- | --- |
| **INTRO\_SYR.** | The next set of questions pertain to syringe services provided by your program between January 1, [YEAR], and December 31, [YEAR]. |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **SYR1.** | | **How many total sterile syringes did your program provide to clients? Please provide your best estimate if records are not readily available. If you do not know or prefer not to answer, you may leave the response blank.** | | |
| NUMSYR | | Number of sterile syringes provided | |  |
|  | \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ |  |  |
|  | Range | 0-9999999 |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **SYR2.** | **Did your program provide syringes to clients based on the clients’ needs, without any restrictions?** | | |
| CLINEED | Needs-based provision of syringes | |  |
|  | No | 0 |  |
|  | Yes | 1 |  |
|  | Refuse to Answer | 7 |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **SYR3.** | **Did your program provide clients with extra syringes to distribute to other people in the community (i.e., secondary exchange or peer delivery)?** | | |
| SECXCHNG | Secondary exchange | |  |
|  | No | 0 |  |
|  | Yes | 1 |  |
|  | Refuse to Answer | 7 |  |

|  |  |
| --- | --- |
| **Check\_SYR4.** | If R selected ‘Yes’ (SYR3 [SECXCHNG] EQ 1), go to SYR4 [SETRAIN].  Else, go to INTRO\_PN. |

|  |  |  |  |
| --- | --- | --- | --- |
| **SYR4.** | **Did your program provide training or other support for clients to distribute new, sterile syringes to others (i.e., secondary exchange) and/or facilitate syringe disposal?** | | |
| SETRAIN | Secondary exchange training | |  |
|  | No | 0 |  |
|  | Yes | 1 |  |
|  | Refuse to Answer | 7 |  |

PROVISION OF NALOXONE AND OTHER OVERDOSE REVERSAL MEDICATIONS

|  |  |
| --- | --- |
| **INTRO\_PN.** | In this section, we will ask you about overdose prevention services your program may have provided, such as overdose prevention training and naloxone distribution. As a reminder, we are asking about services provided by your program between January 1, [YEAR], and December 31, [YEAR]. |

|  |  |  |  |
| --- | --- | --- | --- |
| **PN1.** | **What overdose prevention or treatment services did your program provide? Select all that apply.** | | |
| WHATOD | What OD prevention or treatment services provided | |  |
|  | None |  |  |
|  | Naloxone kits |  |  |
|  | Naloxone prescription |  |  |
|  | Fentanyl test strips |  |  |
|  | Overdose prevention and response training for opioids |  |  |
|  | Overdose prevention and response training for drugs other than opioids (e.g., cocaine, methamphetamine) |  |  |
|  | Refuse to Answer | 77 |  |

|  |  |
| --- | --- |
| **Check\_PN2.** | If R provided naloxone kits (PN1 [WHATOD] EQ 1), go to PN2 [NALKIT].  Else, go to INTRO\_PS1. |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **PN2.** | | **How many naloxone kits were distributed by your program? Please provide the number of kits distributed regardless of how many doses were contained in each kit. If your program does not collect these data, please provide your best estimate. If you do not know or prefer not to answer, you may leave the response blank.** | | |
| NALKIT | | Number of naloxone kits distributed | |  |
|  | \_\_ \_\_ \_\_ \_\_ |  |  |
|  | Range | 0-9999 |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **PN3.** | | **How many doses were distributed in each naloxone kit by your program? If you do not know or prefer not to answer, you may leave the response blank.** | | |
| NALDOS | | Number of doses distributed in each naloxone kit | |  |
|  | \_\_ \_\_ |  |  |
|  | Range | 1-99 |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **PN4.** | **In what ways did your program distribute naloxone kits? Select all that apply.** | | |
| NALDIS | How distributed naloxone | |  |
|  | Direct distribution from staff to client |  |  |
|  | In-person delivery (kit delivered directly to client) |  |  |
|  | Mail delivery (kit mailed to client) |  |  |
|  | Secondary distribution (client distributes kit to peers) |  |  |
|  | Provider referral for prescription or referral to pharmacy |  |  |
|  | Offered at community-based overdose education events (open to the public) |  |  |
|  | Offered at overdose education events for staff or clients of other organizations |  |  |
|  | Refuse to Answer | 7 |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **PN5.** | **What barriers, if any, did your program experience in providing naloxone to your clients? Select all that apply.** | | |
| BARNAL | Barriers to providing naloxone | |  |
|  | No barriers |  |  |
|  | High cost of naloxone |  |  |
|  | Shortage of naloxone |  |  |
|  | Legal/political climate |  |  |
|  | Other (please describe) |  |  |
|  | Don’t Know | 9 |  |
|  | Refuse to Answer | 7 |  |

|  |  |
| --- | --- |
| **Check\_PN5spec.** | If R selected ‘Other (please describe)’ (PN5(5) [BARNAL(5)] EQ 1), go to PN5spec [BARNAL\_S].  Else, go to INTRO\_PS1. |

|  |  |  |  |
| --- | --- | --- | --- |
| **PN5spec.** | **Specify other barrier in providing naloxone** |  | |
| BARNAL\_S | Specify other barrier in providing naloxone |  | |
|  | \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ | |
|  | {text response; max characters = 255} | | |

PROVISION OF SERVICES

|  |  |
| --- | --- |
| **INTRO\_PS1.** | The next set of questions are about the services your program provided or needed between January 1, [YEAR], and December 31, [YEAR]. This information will help us understand the services that programs are already providing, trying to expand, or adding to meet client needs. Please indicate next to each service whether your program 1) *fully provided* *the service* (that is, the service was provided at a level that fully met client needs), 2) *partially provided* *the service* (that is, the service was provided inconsistently or at a level that did not meet client needs), 3) *did not provide the service and was not able to meet client needs*, or 4) *did not provide the service and most clients did not need the service*. If service provision varied between January 1, [YEAR], and December 31, [YEAR], choose the option that best describes the provision of services during the majority of time during this period. |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **PS1.** | | **For each of the following safer injection and drug use supplies, please indicate the extent to which the supply was provided.** | | | | | | |
| INJSUP | | Safer injection and drug use supplies | | | |  | | |
|  | |  | Fully provided | Partially provided | Not providedbut needed | | Not provided and not needed | Refuse to Answer/  Not Applicable |
| INJSUPA | Syringes |  |  |  | |  |  |
| INJSUPB | Cookers |  |  |  | |  |  |
| INJSUPC | Cottons |  |  |  | |  |  |
| INJSUPD | Syringe/pill filters like Sterifilt® |  |  |  | |  |  |
| INJSUPE | Saline or sterile water |  |  |  | |  |  |
| INJSUPF | Ties/tourniquets |  |  |  | |  |  |
| INJSUPG | Alcohol pads |  |  |  | |  |  |
| INJSUPH | Wound care kits |  |  |  | |  |  |
| INJSUPI | Sharps containers for carrying used syringes |  |  |  | |  |  |
| INJSUPJ | Fentanyl test strips |  |  |  | |  |  |
| INJSUPK | Safer smoking kits |  |  |  | |  |  |
| INJSUPL | Other (please describe) |  |  |  | |  |  |

|  |  |
| --- | --- |
| **Check\_PS1spec.** | If R selected ‘Other (please describe)’ (PS1 [INJSUPL]), go to PS1spec [INJSUP\_S].  Else, go to PS2 [SEXSUP]. |

|  |  |  |  |
| --- | --- | --- | --- |
| **PS1spec.** | **Specify other injection and drug use supplies** |  | |
| INJSUP\_S | Specify other injection and drug use supplies |  | |
|  | \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ | |
|  | {text response; max characters = 100} | | |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **PS2.** | | **For each of the following safer sex supplies, please indicate the extent to which the supply was provided.** | | | | | | |
| SEXSUP | | Safer sex supplies | | | |  | | |
|  | |  | Fully provided | Partially provided | Not providedbut needed | | Not provided and not needed | Refuse to Answer |
| SEXSUPA | External condoms (male condoms) |  |  |  | |  |  |
| SEXSUPB | Internal condoms (female condoms) |  |  |  | |  |  |
| SEXSUPC | Lubricant |  |  |  | |  |  |
| SEXSUPD | Dental dams |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **PS3.** | | **For each of the following testing services, please indicate the extent to which the service was provided onsite, either by the program itself or by partners, at the location(s) where your program operated.** | | | | | | |
| ONTEST | | Onsite testing services | | | |  | | |
|  | |  | Fully provided | Partially provided | Not provided but needed | | Not provided and not needed | Refuse to Answer/  Not Applicable |
| ONTESTA | HIV rapid testing |  |  |  | |  |  |
| ONTESTB | HIV laboratory-based testing |  |  |  | |  |  |
| ONTESTC | Hepatitis C virus (HCV) rapid testing |  |  |  | |  |  |
| ONTESTD | Hepatitis C virus (HCV) laboratory-based testing |  |  |  | |  |  |
| ONTESTE | STI testing other than hepatitis or HIV |  |  |  | |  |  |
| ONTESTF | TB skin testing or laboratory-based screening for latent TB |  |  |  | |  |  |
| ONTESTG | Pregnancy testing |  |  |  | |  |  |
| ONTESTH | COVID-19 testing |  |  |  | |  |  |
| ONTESTI | Other (please describe) |  |  |  | |  |  |

|  |  |
| --- | --- |
| **Check\_PS3spec.** | If R selected ‘Other (please describe)’ (PS3 [ONTESTI]), go to PS3spec [ONTEST\_S].  Else, go to PS4 [ONVAX]. |

|  |  |  |  |
| --- | --- | --- | --- |
| **PS3spec.** | **Specify other onsite testing service** |  | |
| ONTEST\_S | Specify other testing |  | |
|  | \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ | |
|  | {text response; max characters = 100} | | |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **PS4.** | | **For each of the following vaccinations, please indicate the extent to which the service was provided onsite, either by the program itself or by partners, at the location(s) where your program operated.** | | | | | | |
| ONVAX | | Onsite vaccinations | | | |  | | |
|  | |  | Fully provided | Partially provided | Not provided but needed | | Not provided and not needed | Refuse to Answer/  Not Applicable |
| ONVAXA | Hepatitis A vaccination |  |  |  | |  |  |
| ONVAXB | Hepatitis B vaccination |  |  |  | |  |  |
| ONVAXC | Influenza vaccination |  |  |  | |  |  |
| ONVAXD | COVID-19 vaccination |  |  |  | |  |  |
| ONVAXE | Other (please describe) |  |  |  | |  |  |

|  |  |
| --- | --- |
| **Check\_PS4spec.** | If R selected ‘Other (please describe)’ (PS4 [ONVAXE]), go to PS4spec [ONVAX\_S].  Else, go to PS5 [ONMED]. |

|  |  |  |  |
| --- | --- | --- | --- |
| **PS4spec.** | **Specify other vaccination** |  | |
| ONVAX\_S | Specify other vaccination |  | |
|  | \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ | |
|  | {text response; max characters = 100} | | |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **PS5.** | | **For each of the following medications, please indicate the extent to which the medication was prescribed and/or dispensed onsite, either by the program itself or by partners, at the location(s) where your program operated.** | | | | | | |
| ONMED | | Onsite medications | | | |  | | |
|  | |  | Fully provided | Partially provided | Not provided but needed | | Not provided and not needed | Refuse to Answer/  Not Applicable |
| ONMEDA | HIV treatment |  |  |  | |  |  |
| ONMEDB | PrEP (pre-exposure prophylaxis) |  |  |  | |  |  |
| ONMEDC | PEP (post-exposure prophylaxis) |  |  |  | |  |  |
| ONMEDD | Hepatitis C treatment |  |  |  | |  |  |
| ONMEDE | STI treatment other than hepatitis or HIV |  |  |  | |  |  |
| ONMEDF | Medications for opioid use disorder (MOUD) |  |  |  | |  |  |
| ONMEDG | Medications for non-opioid substance use disorders |  |  |  | |  |  |
| ONMEDH | Medications for mental health disorders |  |  |  | |  |  |
| ONMEDI | Other (please describe) |  |  |  | |  |  |

|  |  |
| --- | --- |
| **Check\_PS5spec.** | If R selected ‘Other (please describe)’ (PS5 [ONMEDI]), go to PS5spec [ONMED\_S].  Else, go to Check\_PS6. |

|  |  |  |  |
| --- | --- | --- | --- |
| **PS5spec.** | **Specify other medication** |  | |
| ONMED\_S | Specify other medication |  | |
|  | \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ | |
|  | {text response; max characters = 100} | | |

|  |  |
| --- | --- |
| **Check\_PS6.** | If R provided MOUD (PS5 [ONMEDF] EQ “Fully provided” OR “Partially provided”), go to PS6 [MOUD\_S].  Else, go to PS7 [ONMSRV]. |

|  |  |  |  |
| --- | --- | --- | --- |
| **PS6.** | **You indicated that your program provided onsite medications for opioid use disorders (MOUD) between January 1, [YEAR], and December 31, [YEAR]. Which of the following MOUD did your program provide onsite, either by the program itself or by partners, at the location(s) where your program operated? Select all that apply.** | | |
| MOUD\_S | Which MOUD provided | |  |
|  | Buprenorphine/naloxone (Suboxone) |  |  |
|  | Buprenorphine (Subutex) |  |  |
|  | Methadone |  |  |
|  | Naltrexone (Vivitrol) |  |  |
|  | Other (please describe) |  |  |
|  | Refuse to Answer | 7 |  |

|  |  |
| --- | --- |
| **Check\_PS6spec.** | If R selected ‘Other (please describe)’ (PS6 [MOUD\_S]), go to PS6spec [MOUD\_SS].  Else, go to PS7 [ONMSRV]. |

|  |  |  |  |
| --- | --- | --- | --- |
| **PS6spec.** | **Specify other MOUD** |  | |
| MOUD\_SS | Specify other MOUD |  | |
|  | \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ | |
|  | {text response; max characters = 100} | | |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **PS7.** | | **For each of the following other medical services, please indicate the extent to which the service was provided onsite, either by the program itself or by partners, at the location(s) where your program operated.** | | | | | | |
| ONMSRV | | Other onsite medical services | | | |  | | |
|  | |  | Fully provided | Partially provided | Not provided but needed | | Not provided and not needed | Refuse to Answer/  Not Applicable |
| ONMSRVA | Substance use disorder treatment services (excluding medications) |  |  |  | |  |  |
| ONMSRVB | Wound care/treatment |  |  |  | |  |  |
| ONMSRVC | Mental health services (excluding medications) provided by a licensed physician, psychologist, nurse practitioner, or social worker |  |  |  | |  |  |
| ONMSRVD | General medical care (primary care or urgent care) |  |  |  | |  |  |
| ONMSRVE | Reproductive health care excluding STI testing (e.g., pap smears) |  |  |  | |  |  |
| ONMSRVF | Family planning, contraception, or prenatal care |  |  |  | |  |  |
| ONMSRVG | Other (please describe) |  |  |  | |  |  |

|  |  |
| --- | --- |
| **Check\_PS7spec.** | If R selected ‘Other (please describe)’ (PS7 [ONMSRVG]), go to PS7spec [ONMSRV\_S].  Else, go to PS8 [CPNAV]. |

|  |  |  |  |
| --- | --- | --- | --- |
| **PS7spec.** | **Specify other onsite medical services** |  | |
| ONMSRV\_S | Specify other onsite medical services |  | |
|  | \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ | |
|  | {text response; max characters = 100} | | |

|  |  |  |  |
| --- | --- | --- | --- |
| **PS8.** | **Did your program provide client navigation services/peer navigation? Client/peer navigation provides individualized support for program clients in accessing and sustaining engagement with health and other services.** | | |
| CPNAV | Did program provide client/peer navigation services | |  |
|  | No | 0 |  |
|  | Yes | 1 |  |
|  | Refuse to Answer | 7 |  |

|  |  |
| --- | --- |
| **Check\_PS9.** | If R provided client/peer navigation services (PS8) [CPNAV] EQ 1), go to PS9 [CPNAV\_S].  Else, go to PS10 [SOCSRV]. |

|  |  |  |  |
| --- | --- | --- | --- |
| **PS9.** | **What services were covered by your client navigation/peer navigation program? Select all that apply.** | | |
| CPNAV\_S | Client/peer navigation services | |  |
|  | HIV care |  |  |
|  | PrEP (pre-exposure prophylaxis for HIV prevention) |  |  |
|  | HCV care |  |  |
|  | Medications for opioid use disorder (MOUD) |  |  |
|  | Medications for non-opioid substance use disorders |  |  |
|  | Legal records (e.g., birth certificate, social security card, state ID/driver’s license) |  |  |
|  | Medicaid or other health insurance |  |  |
|  | Social support services (e.g., housing) |  |  |
|  | Refuse to Answer | 77 |  |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **PS10.** | | **For each of the following social and other services, please indicate the extent to which the service was provided.** | | | | | | |
| SOCSRV | | Social and other services | | | |  | | |
|  | |  | Fully provided | Partially provided | Not provided but needed | | Not provided and not needed | Refuse to Answer/  Not Applicable |
| SOCSRVA | Case management |  |  |  | |  |  |
| SOCSRVB | Childcare |  |  |  | |  |  |
| SOCSRVC | Drop-in center |  |  |  | |  |  |
| SOCSRVD | Enrollment in Medicaid or other health insurance |  |  |  | |  |  |
| SOCSRVE | Family violence, domestic violence, or intimate partner violence services |  |  |  | |  |  |
| SOCSRVF | Food/meals, including SNAP, WIC, food pantries, or meal delivery services |  |  |  | |  |  |
| SOCSRVG | Housing support |  |  |  | |  |  |
| SOCSRVH | Hygiene-related services (e.g., laundry, showers) |  |  |  | |  |  |
| SOCSRVI | Job-related services (e.g., placement assistance, skills training) |  |  |  | |  |  |
| SOCSRVJ | Legal services/counseling |  |  |  | |  |  |
| SOCSRVK | Substance use counseling provided by certified addiction counselors or other recovery support services |  |  |  | |  |  |
| SOCSRVL | Other (please describe) |  |  |  | |  |  |

|  |  |
| --- | --- |
| **Check\_PS10spec.** | If R selected ‘Other (please describe)’ (PS10) [SOCSRVL]), go to PS10spec [SOCSRV\_S].  Else, go to INTRO\_PS2. |

|  |  |  |  |
| --- | --- | --- | --- |
| **PS10spec.** | **Specify other social service** |  | |
| SOCSRV\_S | Specify other social service |  | |
|  | \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ | |
|  | {text response; max characters = 100} | | |

|  |  |
| --- | --- |
| **INTRO\_PS11.** | The next questions pertain to referrals provided by your program between January 1, [YEAR], and December 31, [YEAR]. By “referral,” we mean directing clients to specific offsite providers where they can receive specific services. |

|  |  |  |  |
| --- | --- | --- | --- |
| **PS11.** | **What types of referrals to testing services did your program provide? Select all that apply.** | | |
| REFTEST | Testing referrals | |  |
|  | No testing referrals provided |  |  |
|  | HIV testing |  |  |
|  | Hepatitis C virus (HCV) testing |  |  |
|  | STI testing other than hepatitis or HIV |  |  |
|  | TB skin testing or laboratory-based screening for latent TB |  |  |
|  | Pregnancy testing |  |  |
|  | COVID-19 testing |  |  |
|  | Other (please describe) |  |  |
|  | Refuse to Answer | 77 |  |

|  |  |
| --- | --- |
| **Check\_PS11spec.** | If R selected ‘Other (please describe)’ (PS11(8) [REFTEST(8)] EQ 1), go to PS11spec [REFTEST\_S].  Else, go to PS12 [RCOVAX]. |

|  |  |  |  |
| --- | --- | --- | --- |
| **PS11spec.** | **Specify other testing referral** |  | |
| REFTEST\_S | Specify other testing referral |  | |
|  | \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ | |
|  | {text response; max characters = 100} | | |

|  |  |  |  |
| --- | --- | --- | --- |
| **PS12.** | **What types of referrals for vaccinations did your program provide? Select all that apply.** | | |
| REFVAX | Vaccination referral | |  |
|  | No vaccination referrals provided |  |  |
|  | Hepatitis A vaccination |  |  |
|  | Hepatitis B vaccination |  |  |
|  | Influenza vaccination |  |  |
|  | COVID-19 vaccination |  |  |
|  | Other (please describe) |  |  |
|  | Refuse to Answer | 77 |  |

|  |  |
| --- | --- |
| **Check\_PS12spec.** | If R selected ‘Other (please describe)’ (PS12(6) [REFVAX(6)] EQ 1), go to PS12spec [REFVAX\_S].  Else, go to PS13 [REFMED]. |

|  |  |  |  |
| --- | --- | --- | --- |
| **PS12spec.** | **Specify other vaccination referral** |  | |
| REFVAX\_S | Specify other vaccination referral |  | |
|  | \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ | |
|  | {text response; max characters = 100} | | |

|  |  |  |  |
| --- | --- | --- | --- |
| **PS13.** | **What types of referrals to treatment did your program provide? Select all that apply.** | | |
| REFMED | Referrals to treatment | |  |
|  | No treatment referrals provided |  |  |
|  | HIV treatment |  |  |
|  | PrEP (pre-exposure prophylaxis) |  |  |
|  | PEP (post-exposure prophylaxis) |  |  |
|  | Hepatitis C treatment |  |  |
|  | STI treatment other than hepatitis or HIV |  |  |
|  | Buprenorphine (including Suboxone or Subutex) |  |  |
|  | Medications for opioid use disorder (MOUD) other than buprenorphine |  |  |
|  | Naloxone |  |  |
|  | Medications for non-opioid substance use disorders |  |  |
|  | Medications for mental health disorders |  |  |
|  | Other (please describe) |  |  |
|  | Refuse to Answer | 77 |  |

|  |  |
| --- | --- |
| **Check\_PS13spec.** | If R selected ‘Other (please describe)’ (PS13(12) [REFMED(12)] EQ 1), go to PS13spec [REFMED\_S].  Else, go to PS14 [RMSRV]. |

|  |  |  |  |
| --- | --- | --- | --- |
| **PS13spec.** | **Specify other treatment referral** |  | |
| REFMED\_S | Specify other treatment referral |  | |
|  | \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ | |
|  | {text response; max characters = 100} | | |

|  |  |  |  |
| --- | --- | --- | --- |
| **PS14.** | **What types of referrals to other medical services did your program provide? Select all that apply.** | | |
| RMSRV | Other medical services referrals | |  |
|  | No referrals to other medical services provided |  |  |
|  | Substance use disorder treatment services (excluding medications) |  |  |
|  | Wound care/treatment |  |  |
|  | Mental health services (excluding medications) provided by a licensed physician, psychologist, nurse practitioner, or social worker |  |  |
|  | General medical care (primary care or urgent care) |  |  |
|  | Reproductive health care excluding STI testing (e.g., pap smears) |  |  |
|  | Family planning, contraception, or prenatal care |  |  |
|  | Other (please describe) |  |  |
|  | Refuse to Answer | 77 |  |

|  |  |
| --- | --- |
| **Check\_PS14spec.** | If R selected ‘Other (please describe)’ (PS14(8) [RMSRV(8)] EQ 1), go to PS14spec [RMSRV\_S].  Else, go to INTRO\_MD1. |

|  |  |  |  |
| --- | --- | --- | --- |
| **PS14spec.** | **Specify other medical services referrals** |  | |
| RMSRV\_S | Specify other medical services referrals |  | |
|  | \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ | |
|  | {text response; max characters = 100} | | |

2020 MODULE

|  |  |
| --- | --- |
| **INTRO\_MD1.** | Next, we would like to ask you a few questions about the services you provided in 2020. |

|  |  |  |  |
| --- | --- | --- | --- |
| **MD1.** | **Did your program provide any services at any time between January 1, 2020, and December 31, 2020?** | | |
| OP20 | Operated during 2020 | |  |
|  | No | 0 |  |
|  | Yes | 1 |  |

|  |  |
| --- | --- |
| **Check\_MD1.** | If R did not operate at any time during 2020 (MD1 [OP20] EQ 0), go to INTRO\_PE.  Else, go to INTRO\_MD2. |

|  |  |
| --- | --- |
| **INTRO\_MD2.** | The next set of questions is about the services your program provided from January 1, 2020, to December 31, 2020. To the extent possible, please refer to your records to answer these questions. If your program only operated during some of this time period, please provide information reflective of the time period(s) during which your program did operate. |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **MD2.** | | **How many unique clients did your program serve between January 1, 2020, and December 31, 2020? Please provide the best estimate to your knowledge. If you do not know or prefer not to answer, you may leave the response blank.** | | |
| CLI20 | | Number of unique clients | |  |
|  | \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ |  |  |
|  | Range | 0-99999999 |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **MD3.** | | **Between January 1, 2020, and December 31, 2020, how many total sterile syringes did your program provide to clients? Please provide your best estimate if records are not readily available. If you do not know or prefer not to answer, you may leave the response blank.** | | |
| SYR20 | | Number of sterile syringes provided | |  |
|  | \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ |  |  |
|  | Range | 0-9999999 |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **MD4.** | **Between January 1, 2020, and December 31, 2020, did your program provide syringes to clients based on the clients’ needs, without any restrictions?** | | |
| NEED20 | Needs-based provision of syringes | |  |
|  | No | 0 |  |
|  | Yes | 1 |  |
|  | Don’t Know | 9 |  |
|  | Refuse to Answer | 7 |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **MD5.** | **Did your program distribute naloxone kits between January 1, 2020, and December 31, 2020?** | | |
| ONNAL20 | Onsite naloxone distribution | |  |
|  | No | 0 |  |
|  | Yes | 1 |  |
|  | Don’t Know | 9 |  |
|  | Refuse to Answer | 7 |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **MD6.** | | **What was your total program budget between January 1, 2020, and December 31, 2020? If your program is part of a larger, multi-service organization, please only provide the budget for your part of the program. Please provide the best estimate to your knowledge.** | | |
| BUDG20 | | Total program budget | |  |
|  | Less than $25,000 | 1 |  |
|  | $25,000–$100,000 | 2 |  |
|  | $100,001–$250,000 | 3 |  |
|  | $250,001–$500,000 | 4 |  |
|  | $500,001–$1 million | 5 |  |
|  | Between $1 million and $2 million | 6 |  |
|  | $2 million or more | 7 |  |
|  | Don’t Know | 99 |  |
|  | Refuse to Answer | 77 |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **MD7.** | **Which of the following testing services were provided onsite, either by the program itself or by partners, at the location(s) where your program operated between January 1, 2020, and December 31, 2020? Select all that apply.** | | |
| ONTST20 | Onsite testing services | |  |
|  | No testing services were provided onsite |  |  |
|  | HIV rapid testing |  |  |
|  | HIV laboratory-based testing |  |  |
|  | Hepatitis C virus (HCV) rapid testing |  |  |
|  | Hepatitis C virus (HCV) laboratory-based testing |  |  |
|  | Don’t Know | 99 |  |
|  | Refuse to Answer | 77 |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **MD8.** | **Which of the following medications for opioid use disorder (MOUD) were provided onsite, either by the program itself or by partners, at the location(s) where your program operated between January 1, 2020, and December 31, 2020? Select all that apply.** | | |
| ONMOUD20 | Onsite MOUD | |  |
|  | No medications were provided onsite |  |  |
|  | Buprenorphine/naloxone (Suboxone) |  |  |
|  | Buprenorphine (Subutex) |  |  |
|  | Methadone |  |  |
|  | Naltrexone (Vivitrol) |  |  |
|  | Other (please describe) |  |  |
|  | Don’t Know | 99 |  |
|  | Refuse to Answer | 77 |  |

|  |  |
| --- | --- |
| **Check\_MD8spec.** | If R selected ‘Other (please specify)’ (MD8(6) [ONMOUD20(6)] EQ 1), go to MD8spec [ONMOUD20\_S].  Else, go to MD9[ONMSRV20]. |

|  |  |  |  |
| --- | --- | --- | --- |
| **MD8spec.** | **Specify other MOUD provided onsite.** |  | |
| ONMOUD20\_S | Specify other MOUD |  | |
|  | \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ | |
|  | {text response; max characters = 100} | | |

|  |  |  |  |
| --- | --- | --- | --- |
| **MD9.** | **Which of the following other medical services were provided onsite, either by the program itself or by partners, at the location(s) where your program operated between January 1, 2020, and December 31, 2020? Select all that apply.** | | |
| ONMSRV20 | Onsite other medical services | |  |
|  | No other medical services were provided onsite |  |  |
|  | Substance use disorder treatment services (excluding medications) |  |  |
|  | Wound care/treatment |  |  |
|  | Mental health services (excluding medications) provided by a licensed physician, psychologist, nurse practitioner, or social worker |  |  |
|  | General medical care (primary care or urgent care) |  |  |
|  | Reproductive health care excluding STI testing (e.g., pap smears) |  |  |
|  | Family planning, contraception, or prenatal care |  |  |
|  | Don’t Know | 99 |  |
|  | Refuse to Answer | 77 |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **MD10.** | **Did your program provide referrals for buprenorphine (including Suboxone or Subutex) between January 1, 2020, and December 31, 2020?** | | |
| RFBUP20 | Referrals to buprenorphine | |  |
|  | No | 0 |  |
|  | Yes | 1 |  |
|  | Don’t Know | 9 |  |
|  | Refuse to Answer | 7 |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **MD11.** | **Between January 1, 2020, and December 31, 2020, what types of referrals to other medical services did your program provide? Select all that apply.** | | |
| RMSRV20 | Other medical services referrals | |  |
|  | No referrals to other medical services provided |  |  |
|  | Substance use disorder treatment services (excluding medications) |  |  |
|  | Wound care/treatment |  |  |
|  | Mental health services (excluding medications) provided by a licensed physician, psychologist, nurse practitioner, or social worker |  |  |
|  | General medical care (primary care or urgent care) |  |  |
|  | Reproductive health care excluding STI testing (e.g., pap smears) |  |  |
|  | Family planning, contraception, or prenatal care |  |  |
|  | Don’t Know | 99 |  |
|  | Refuse to Answer | 77 |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **MD12.** | | **How was your program impacted by the COVID-19 pandemic in 2020? Select all that apply.** | | |
| COV20 | | COVID-19 impacts | |  |
|  | Reduced hours or days of operation |  |  |
|  | Reduced funding |  |  |
|  | Site closure(s) |  |  |
|  | Staff shortage or loss |  |  |
|  | Change to a MORE restrictive syringe distribution model (e.g., from needs-based to 1-for-1) |  |  |
|  | Change to a LESS restrictive syringe distribution model (e.g., from 1-for-1 to needs-based) |  |  |
|  | Changes in physical space (e.g., moved services outdoors, markers for social distancing, plexiglass) |  |  |
|  | Disruptions in supply of syringes |  |  |
|  | Disruptions in other supplies |  |  |
|  | Disruptions in HIV, HCV, or other bloodborne pathogens testing |  |  |
|  | Disruptions in substance use disorder treatment linkage (e.g., stopped services, new regulatory practices) |  |  |
|  | Changes in other direct client services, such as food distribution, showers, housing assistance. |  |  |
|  | New/increased access to telehealth for clients |  |  |
|  | Lack of personal protective equipment (PPE) |  |  |
|  | Other (please specify) |  |  |
|  | | Program was not impacted by COVID-19 in 2020 |  |  |
|  | Don’t Know | 99 |  |
|  | Refuse to Answer | 77 |  |

|  |  |
| --- | --- |
| **Check\_MD12spec.** | If R selected ‘Other (please specify)’ (MD12(15) [COV20(15)] EQ 1), go to MD12spec [COV20\_S].  Else, go to INTRO\_PE. |

|  |  |  |  |
| --- | --- | --- | --- |
| **MD12spec.** | **Specify other ways your program was impacted by COVID-19.** |  | |
| COV20\_S | Specify other program operator |  | |
|  | \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ | |
|  | {text response; max characters = 100} | | |

PROCESS EVALUATION

|  |  |
| --- | --- |
| **INTRO\_PE.** | We value your input and would like to ask you a few questions about your experience taking this survey so that we can improve it and ensure that the information you provide is useful. |

|  |  |  |  |
| --- | --- | --- | --- |
| **PE1.** | **The length of the survey was…** | | |
| SLNGTH | Survey length | |  |
|  | Too short | 1 |  |
|  | Just right | 2 |  |
|  | Too long | 3 |  |
|  | Refuse to Answer | 7 |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **PE2.** | **If you were taking the survey again, what format would you prefer? Select only one.** | | |
| PREFMT | Preferred survey format | |  |
|  | Self-administered online | 1 |  |
|  | Self-administered via an electronic document (Word or PDF) that can be completed and returned by email | 2 |  |
|  | Interviewer-administered to me over the phone | 3 |  |
|  | Interviewer-administered to me in person | 4 |  |
|  | Refuse to Answer | 7 |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **PE3.** | **What topic(s) were missing from this survey and need to be added in the future?** | | |
| MISTOP | Missing topics |  | |
|  | \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ | |
|  | {text response; max characters = 255} | | |

|  |  |  |  |
| --- | --- | --- | --- |
| **PE4.** | **How would you like to see this information used? Select all that apply.** | | |
| HOWUSE | How this information used | |  |
|  | Increase awareness |  |  |
|  | Increase community support |  |  |
|  | Increase funding |  |  |
|  | Inform policy/law |  |  |
|  | Other (please describe) |  |  |
|  | Refuse to Answer | 7 |  |

|  |  |
| --- | --- |
| **Check\_PE4spec.** | If R selected ‘Other (please describe)’ (PE4(5) [HOWUSE(5)] EQ 1), go to PE4spec [HOWUSE\_S].  Else, go to PE5 [OTHSUG]. |

|  |  |  |  |
| --- | --- | --- | --- |
| **PE4spec.** | **Specify other use for this information** |  | |
| HOWUSE\_S | Specify other use for this information |  | |
|  | \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ | |
|  | {text response; max characters = 100} | | |

|  |  |  |  |
| --- | --- | --- | --- |
| **PE5.** | **Please use the space below for any other suggestions or comments for improving this survey to make it useful to programs.** | | |
| OTHSUG | Other suggestions or comments |  | |
|  | \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ \_\_\_\_ \_\_ \_\_ \_\_ | |
|  | {text response; max characters = 255} | | |

|  |  |
| --- | --- |
| **DATA\_PE.** | You have now completed the survey. Thank you so much for your participation. Once you submit your survey, you will not be able to go back to previous questions or change any of your answers, so please make sure you are ready before proceeding.    Before we end, we would like to document your preference on how information about your program is shared with others aside from the survey team. Others could include, for example, researchers, health department staff, and other syringe services programs. The survey team includes staff at the North American Syringe Exchange Network (NASEN), the University of Washington (UW), New York University (NYU), and the Centers for Disease Control and Prevention (CDC). As a reminder, data from this survey will only be reported in aggregate (that is, your responses will be grouped with those from other programs) in formats like presentations, publications and reports. Program names and any other information that could potentially identify a program, such as the state or county where a program operates, will never be reported. |

|  |  |  |  |
| --- | --- | --- | --- |
| **PE6.** | **Would you be willing to share your data with others aside from the survey team? Please remember that identifying information will never be reported.** | | |
| DATASHR | Individual data sharing preference | |  |
|  | No, data cannot be shared | 0 |  |
|  | Yes, data can be shared | 1 |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **CALC\_EDATE** | **Automatic, hidden variable: Interview end date (today)** | | | |
| **EDATE** | **End date** | |  | |
|  | **\_ \_ / \_ \_ / \_ \_ \_ \_** |  | |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **CALC\_END** | **End time of interview** | |  |
| END | End time | |  |
|  | **\_\_ : \_\_** |  |  |